All News

Dr Irwin Lim Tweet
_connectedcare
Therapeutic gaming (non-immersive environment) Setting & games designed to meet the patient’s goal Patients enter a state of flow & get engaged #ACR19 @rheumnow 4M031 https://t.co/oJ7Ynz0Vvt
Dr. Antoni Chan Tweet
synovialjoints
MAS is a IFNg driven disease. Upstream IL-1 family members IL-18 and IL-33 are important treatment targets in MAS. Behrens E #ACR19 @RheumNow
Philip Robinson Tweet
philipcrobinson
Great question from the audience -> need to be very cautious about thromboembolic issues if thinking about using JAK inhibitors in #lupus #ACR19 @RheumNow Dorner
Mike Putman Tweet
EBRheum
NEW Guidelines for the Management of Polyarteritis Nodosa (PAN) at #ACR19 (in one table!) 1. Go big w/biopsy 2. Cytoxan>Rituxan for severe dx 3. Follow cytoxan with GC sparing agent; stop after 18mos in remission 4. TNF for pts with DADA2 @RheumNow https://t.co/JhNIqVE9jH
David Liew Tweet
drdavidliew
Hep C direct-acting agents have changed the game in Australia. Our national health coverage has a subscription model, and we're edging towards eradication. I suspect our situation mirrors @HopPitieSalpe: new cases of HCV cryo vasculitis are going down #ACR19 ABST1723 @RheumNow https://t.co/upDbGQq3xW
Dr. John Cush Tweet
RheumNow
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.
Gout Study Group Tweet
GoutGroup
How often do US gout patients have #urate testing? The % of the year they have a ULT script? The answers may surprise you...not in a good way. Dr Larry Edwards reviews his presentation at #ACR2019 on health care pathway/treatment for over 1 million #gout patients. @RheumNow https://t.co/Vg1axeEEu4
Mike Putman Tweet
EBRheum
NEW Guidelines for the Management of GCA from #ACR19 in one table 1. Recommend TAB over TA U/S for dx GCA 2. Pts should receive TCZ upfront 3. Don't treat asymptomatic CRP, monitor patients closely Overall in line with my practice, though I'm pro TA U/S @RheumNow https://t.co/4mxcqqi1bA
Dr. Antoni Chan Tweet
synovialjoints

IL-1 blockade beneficial in MAS. Ferritin to ESR ratio useful for identifying these patients. Cytokines Storm Syndrome is one way of thinking of the spectrum of conditions like MAS, HLH, auto inflammatory disease which respond to IL-1 and IL-6 blockade. Cron R #ACR19 @RheumNow

Dr. Paul Sufka Tweet
psufka
Numerous FOAMed (free open access medical education) options for rheumatology: - @RheumNow - @HealioRheum - @HRheuminations - @EBRheum - @RheumJC - @AWIRGROUP #ACR19 https://t.co/cnoEWXfozZ
Dr. Paul Sufka Tweet
psufka
#ACR19 Rheumatology Social Media and the medical professional — @BolekBerqui Thread ⬇️⬇️⬇️ @RheumNow
Dr. John Cush Tweet
RheumNow
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its faculty.
Mike Putman Tweet
EBRheum
So much JAKi right now - RA, PsA, SLE, and more! Last tweet of the day. Curious to hear... Which JAKi do you think will win the JAK-wars? @RheumNow
Kanika Monga, MD Tweet
DrKanikaMonga
My favorite social media ninja -- @psufka shares valuable advice for anyone who wants to jump on the #twitter bandwagon. @cappelliMD joins the party! Distilled + bite-sized information = make the Twittersphere a hit! #ACR19 @RheumNow https://t.co/52und6yfwM
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×